Literature DB >> 29954730

Abiraterone-Olaparib Combo Aids Men with mCRPC.

.   

Abstract

Recent findings from a phase II trial suggest that combining the antiandrogen abiraterone and the PARP inhibitor olaparib significantly improves progression-free survival among patients with metastatic castration-resistant prostate cancer, regardless of their homologous recombination repair-mutation status. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29954730     DOI： 10.1158/2159-8290.CD-NB2018-084

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  2 in total

Review 1.  What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes.

Authors:  Andrea Palicelli; Stefania Croci; Alessandra Bisagni; Eleonora Zanetti; Dario De Biase; Beatrice Melli; Francesca Sanguedolce; Moira Ragazzi; Magda Zanelli; Alcides Chaux; Sofia Cañete-Portillo; Maria Paola Bonasoni; Stefano Ascani; Antonio De Leo; Guido Giordano; Matteo Landriscina; Giuseppe Carrieri; Luigi Cormio; Jatin Gandhi; Davide Nicoli; Enrico Farnetti; Simonetta Piana; Alessandro Tafuni; Martina Bonacini
Journal:  Biomedicines       Date:  2022-01-22

2.  Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition.

Authors:  Kathleen E Fenerty; Michelle Padget; Benjamin Wolfson; Sofia R Gameiro; Zhen Su; John H Lee; Shahrooz Rabizadeh; Patrick Soon-Shiong; James W Hodge
Journal:  J Immunother Cancer       Date:  2018-11-29       Impact factor: 13.751
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.